Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
Vertex presented positive Phase 3 data for ALYFTREK in children with cystic fibrosis ages 2 to 5, showing 65% achieved sweat chloride levels below 30 mmol/L, a marker of near-normal CFTR function. The company plans to initiate global regulatory submissions for this new indication in the first half of 2026, expanding its core franchise into younger pediatric populations.
Key figures
- Drug Name
- ALYFTREK
- Phase Of Trial
- Phase 3
- Alyftrek study n
- 67
- Trikafta study n
- 54
- Alyftrek swcl lt 30 pct
- 65%
- Alyftrek swcl lt 60 pct
- 92%
- Trikafta swcl lt 30 pct
- 68.6%
- Trikafta swcl lt 60 pct
- 98.0%
- Alyftrek long term weeks
- 96
- Cf patients treated globally
- 75000
- Alyftrek study duration weeks
- 24
- Trikafta study duration weeks
- 24
- Alyftrek swcl reduction mmol l
- -9.6
- Trikafta swcl reduction mmol l
- -71.8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.